Wire · founder news, decoded · opportunities
US FDA Approves Sanofi's Wearable Injector Form of Blood Cancer Drug
The US FDA has approved Sarclisa Escena, Sanofi's wearable subcutaneous injector form of a multiple myeloma drug, replacing intravenous infusions and reducing patient time in infusion centres. The approval marks a regulatory win for Sanofi's new leadership as it diversifies beyond its dependency on asthma drug Dupixent.
This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.
The Wire takeaway
If you make wearable injectors, on-body delivery devices, or infusion centre software, Sanofi just proved the market will pay for convenience over IV. Every oncology drug with repeat dosing is now a candidate for this form factor—call the top 20 pharma companies this week.
Read the full story at usnews.com →
Topics: Digital Health · wearable-injectors · oncology · drug-delivery · patient-convenience · fda-approval